Clinical Trials Logo

Adjuvant Chemotherapy clinical trials

View clinical trials related to Adjuvant Chemotherapy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04070313 Terminated - Pancreatic Cancer Clinical Trials

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

Start date: July 11, 2019
Phase: Phase 2
Study type: Interventional

To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. - Primary Endpoint: Relapse-free survival (RFS) - Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile

NCT ID: NCT03858166 Terminated - Ovarian Cancer Clinical Trials

Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer

Start date: December 1, 2017
Phase: Phase 4
Study type: Interventional

This study is a multicenter, open-label, randomized clinical trial. Patients with ovarian cancer receiving postoperative adjuvant chemotherapy were eligible to enroll in this study. Eligible patients were randomly allocated in a "1:1" to "Standard group" ( 6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy) and "Adjusted group" (6mg PEG-rhG-CSF was administrated subcutaneously when ANC < 1000/mm3 after chemotherapy). All patients need to receive at least 2 cycles of PEG-rhG-CSF administration. The primary outcome is the incidence of grade 3/4 neutropenia, and the duration of grade 3/4 neutropenia, the second outcomes are the incidence of FN, neutropenia-related hospitalization, incidence of reduction and delay of chemotherapy dose and safety of PEG-rhG-CSF.

NCT ID: NCT03702868 Terminated - Breast Cancer Clinical Trials

Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer

Start date: October 10, 2018
Phase:
Study type: Observational

Breast cancer is the most common cause of cancer death in women. Adjuvant chemotherapy significantly reduces the risk of recurrence of high-risk breast cancer. However, about 30% of patients still have distant metastasis or local recurrence after chemotherapy. Moreover, 60% of patients had 3-4 degrees of adverse drug reactions during chemotherapy. The purpose of the study is to investigate relationship between gut microbiome and adjuvant chemotherapy in early breast cancer patients.

NCT ID: NCT02492477 Terminated - Solid Tumours Clinical Trials

TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients

Start date: January 2016
Phase: Phase 1
Study type: Interventional

The benefits and risks of flushing or not flushing the non-used PORT-A-CATH® in cancer patients and the time interval of eventual PORT-A-CATH® flushing are currently unknown. The manufacturers of PORT-A-CATH® recommend regular flushings every 4 weeks. In clinical practice, the intervals are usually at least three months. Regular flushing might lead to a decreased risk of PORT-A-CATH® thrombosis, but may also lead to an increased infection or thrombosis rate and patients discomfort. Therefore, this study investigates the safety of not flushing the PORT-A-CATH® for 6 or 12 months.